Premium
Studies on Thrombin Infusion in Dogs
Author(s) -
RØ J. S.,
FLATMARK A.
Publication year - 1972
Publication title -
scandinavian journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0036-553X
DOI - 10.1111/j.1600-0609.1972.tb00942.x
Subject(s) - fibrinolysis , disseminated intravascular coagulation , platelet , thrombin , fibrinogen , coagulation , medicine , haemolysis , hematocrit , thrombin time , endocrinology , immunology , chemistry , anesthesia , partial thromboplastin time
Intravascular coagulation, haemolysis and strong secondary fibrinolysis were induced by thrombin infusion in 6 dogs. Trasylolr̀ treatment increased the consumption of clotting factors and platelets, increased haemolysis, but markedly inhibited the secondary fibrinolysis. One of these 5 dogs died with demonstrable thrombi in lungs and kidneys. Prolonged thrombin and reptilase clotting times coincided with high amounts of fibrinogen degradation products (FDP). In the initial stage of fibrinolysis plasminogen and proteolytic capacity was normal. A delayed drop in these assays was observed, concomitantly with normal FDP. This drop largely indicated a sustained plasminogen consumption due to continuous fibrinolysis initiated by residual thrombi and/or subclinical clotting. A transient leucopenia, relatively more pronounced than the platelet reduction, was found following thrombin infusion, even in dogs treated with kallikrein inhibitor. This suggests that leucocyte counting may be valuable in diagnosing disseminated intravascular coagulation. Thrombin infusion induced low Thrombotest, but unchanged Normotest values, although these assays are considered to measure the same factors (II/VII/X). The discrepancy was less in Trasylolr̀‐treated dogs.